COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration

Luuk B. Hilbrands, Raphal Duivenvoorden, ERACODA Collaborators, Priya Vart, Casper F.M. Franssen, Marc H. Hemmelder, Kitty J. Jager, Lyanne M. Kieneker, Marlies Noordzij, Michelle J. Pena, Hanne de Vries, David Arroyo, Adrian Covic, Marta Crespo, Eric Goffin, Mahmud Islam, Ziad A. Massy, Nuria Montero, João P. Oliveira, Ana Roca MuñozJ. Emilio Sanchez, Sivakumar Sridharan, Rebecca Winzeler, Ron T. Gansevoort*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

323 Citations (Scopus)
39 Downloads (Pure)

Abstract

Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 6 13 and 67 6 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P ¼ 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n ¼ 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07–0.56, P < 0.01). Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

Original languageEnglish
Pages (from-to)1973-1983
Number of pages11
JournalNephrology Dialysis Transplantation
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 2020

Bibliographical note

FUNDING
The ERACODA Consortium is financially supported by unrestricted grants from the ERA-EDTA, the Dutch Kidney Foundation, Baxter and Sandoz. None of these organizations
had any role in the design or execution of the study, nor in
writing of the manuscript.

Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Fingerprint

Dive into the research topics of 'COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration'. Together they form a unique fingerprint.

Cite this